bioRxivCancer Biology
Phenotypic Switching of Naïve T cells to Immune-suppressive Treg-like Cells by Mutant KRAS
A. Kalvala, P. Wallet, L. Yang, C. Wang, H. Li, A. Nam, A. Nathan, I. Mambetsariev, V. Poroyko, H. Gao, P. Chu, M. Sattler, A. Bild, E. R. Manuel, P. P. Lee, M. K. Jolly, P. Kulkarni, R. Salgia
Abstract
Oncogenic (mutant) Ras protein Kirsten rat sarcoma viral oncogene homolog (KRAS) promotes uncontrolled proliferation, altered metabolism, and loss of genome integrity in a cell-intrinsic manner. Here, we demonstrate that CD4+ T cells when incubated with tumor-derived exosomes from mutant (MT) KRAS non-small cell lung cancer (NSCLC) cells, patient sera, or a mouse xenograft model, induce phenotypic conversion to FOXP3+ Treg-like cells that are immune-suppressive. Furthermore, transfecting T cells with MT KRAS cDNA alone induced phenotypic switching and mathematical modeling supported this conclusion. Single-cell sequencing identified the interferon pathway as the mechanism underlying the phenotypic switch. These observations highlight a novel cytokine-independent, cell-extrinsic role for KRAS in T cell phenotypic switching. Thus, targeting this new class of Tregs represents a unique therapeutic approach for NSCLC. Since KRAS is the most frequently mutated oncogene in a wide variety of cancers, the findings of this investigation are likely to be of broad interest and have a large scientific impact.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A new ferrocene derivative blocks KRAS localization and function by oxidative modification at His95.
K. M. Rehl, J. Selvakumar, … K.-J. Cho·bioRxiv·Mar 28, 2023
- Modulation of fibroblasts phenotype by colorectal cancer cells-secreted factors is mostly independent of oncogenic KRAS
P. Dias Carvalho, S. Mendonca, … S. Velho·CellsPeer-reviewed·Aug 11, 2022
- CD16-158-VALINE CHIMERIC RECEPTOR T CELLS OVERCOME THE RESISTANCE OF KRAS-MUTATED COLORECTAL CARCINOMA CELLS TO CETUXIMAB
R. Arriga, S. Caratelli, … G. Sconocchia·bioRxiv·Mar 26, 2019
- An in vivo inflammatory loop potentiates KRAS blockade
K. A. Arendt, G. Ntaliarda, … G. T. Stathopoulos·bioRxiv·Apr 19, 2020
- FLIP is essential for oncogenic KRAS-driven lung cancer
Claudia Hamilton, Shaun Sharkey, … Daniel B. Longley·bioRxiv·Aug 5, 2026
- Silencing of oncogenic KRAS by mutant-selective small interfering RNA
B. Papke, S. H. Azam, … C. V. Pecot·bioRxiv·Oct 8, 2020